These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9512874)

  • 1. Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients.
    Chen MF; Hsu HC; Lee YT
    Cardiovasc Drugs Ther; 1997 Dec; 11(6):787-93. PubMed ID: 9512874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
    Thallinger C; Urbauer E; Lackner E; Graselli U; Kostner K; Wolzt M; Joukhadar C
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):551-7. PubMed ID: 16372516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies.
    Hoffman R; Brook GJ; Aviram M
    Atherosclerosis; 1992 Mar; 93(1-2):105-13. PubMed ID: 1596293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
    Chen MF; Wang TD; Yeh HT; Hsu HC; Lee YT
    Eur J Clin Invest; 2001 Aug; 31(8):707-13. PubMed ID: 11473572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
    Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
    Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men.
    Porkkala-Sarataho E; Nyyssönen K; Salonen JT
    Atherosclerosis; 1996 Jul; 124(1):83-94. PubMed ID: 8800496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
    Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF
    Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation.
    Portal VL; Moriguchi EH; Vieira J; Schio S; Mastalir ET; Buffé F; Bortolini EB; Brüch RS; Rodrigues R
    Arq Bras Cardiol; 2003 Feb; 80(2):156-61, 150-5. PubMed ID: 12640509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits.
    Yasuhara M; Suzumura K; Tanaka K; Takahashi M; Aoki S; Odawara A; Narita H; Suzuki T
    Biol Pharm Bull; 2000 May; 23(5):570-4. PubMed ID: 10823666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881.
    Feldman DL; Mogelesky TC; Sharif R; Sawyer WK; Jeune M; Hu CW; Leonards KS; Prescott MF
    Atherosclerosis; 1999 Jun; 144(2):343-55. PubMed ID: 10407495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression.
    Salonen R; Nyssönen K; Porkkala-Sarataho E; Salonen JT
    Am J Cardiol; 1995 Sep; 76(9):34C-39C. PubMed ID: 7572684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pravastatin on fatty acid profile of low density lipoprotein in patients with hypercholesterolemia.
    Hong CY; Lin SJ; Chang MS; Chiang BN; Shen PM; Shiao MS
    Prostaglandins Leukot Essent Fatty Acids; 1993 Feb; 48(2):155-8. PubMed ID: 8446653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia.
    Napoli C; Postiglione A; Triggiani M; Corso G; Palumbo G; Carbone V; Ruocco A; Ambrosio G; Montefusco S; Malorni A; Condorelli M; Chiariello M
    Atherosclerosis; 1995 Dec; 118(2):259-73. PubMed ID: 8770320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease.
    Orem A; Yandi YE; Vanizor B; Cimşit G; Uydu HA; Malkoç M
    Clin Biochem; 2002 May; 35(3):217-24. PubMed ID: 12074830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
    Nagyová A; Raslová K; Ginter E
    Physiol Res; 1998; 47(3):185-90. PubMed ID: 9803483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients.
    Inoue T; Hayashi M; Takayanagi K; Morooka S
    Atherosclerosis; 2002 Feb; 160(2):369-76. PubMed ID: 11849660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin inhibits oxidative modification of low-density lipoprotein particles in normolipidemic post-menopausal women.
    Wakatsuki A; Okatani Y; Ikenoue N; Izumiya C; Kaneda C
    J Pineal Res; 2000 Apr; 28(3):136-42. PubMed ID: 10739299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells.
    Walters-Laporte E; Furman C; Fouquet S; Martin-Nizard F; Lestavel S; Gozzo A; Lesieur D; Fruchart JC; Duriez P; Teissier E
    J Cardiovasc Pharmacol; 1998 Oct; 32(4):582-92. PubMed ID: 9781926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.